84-3518-41　［取扱停止］LRRK2 (Leucine-rich Repeat Kinase 2, Leucine-rich Repeat Serine/threonine Protein Kinase 2, AURA17, Dardarin, PARK8, RIPK7, ROCO2) (HRP) 200ul　L4502-20G-HRP

特徴

• Parkinson is the second most common neurodegenerative disease after Alzheimers.
• About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease.
• The mutation is the most common cause of Parkinson's disease identified to date.
• LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease.
• By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation).
• It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism.
• LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.
• Applications:Suitable for use in ELISA, Western Blot, and Immunohistochemistry.
• Other applications not tested.
• Recommended Dilution:ELISA: 1:1,000Western Blot: 1:100-1:500Immunohistochemistry: 1:10-1:50Optimal dilutions to be determined by the researcher.
• Storage and Stability:Store product at 4°C if to be used immediately within two weeks.
• For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C.
• Aliquots are stable at -20°C for 12 months after receipt.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Note: Applications are based on unconjugated antibody.